[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperuricemia-or-gout\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperuricemia-or-gout":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,72,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100580202","phase-4-effect-of-dotinurad-in-hyperuricemia-with-hypertension-100580202",false,"NCT06834230","Effect of Dotinurad in Hyperuricemia With Hypertension","Effect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)","DIANA-NEXT","Inclusion Criteria:\n\n1. Patients aged 20 years or older at the time of consent (regardless of gender)\n2. Patients with hyperuricemia with serum uric acid level \\>7.0 mg\u002FdL who have not received any urate lowering drug within 27 days prior to obtaining consent, or patients who were receiving urate lowering drugs at the time of obtaining consent but have been off the drugs for more than 27 days\n3. Hypertensive patients who meet the definition of hypertension in the latest Hypertension Treatment Guidelines of the Japanese Society of Hypertension and whose treatment for hypertension (with or without drug therapy) has not changed within 4 weeks prior to eligibility determination\n4. Patients who have given written consent to participate in this study\n\nExclusion Criteria:\n\n1. Patients with unsettled gout after acute gouty arthritis\n2. Patients currently suffering from urinary tract stones\n3. Patients with known secondary hyperuricemia who have Lesch-Nyhan syndrome, hyperphosphoribosyl pyrophosphate synthase, congenital myogenic hyperuricemia, hematopoietic tumors (acute leukemia, malignant lymphoma, myeloproliferative disorders, myelodysplastic syndrome), solid tumors (breast cancer, seminoma, sarcoma, Wilms' tumor, small cell lung cancer), non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia vera, hemolytic anemia), tumor melting syndrome, rhabdomyolysis, hypothyroidism, polycystic kidney disease, lead poisoning\u002Flead nephropathy, Down syndrome, familial juvenile gout nephropathy, hyperlactatemia, or type 1 glycogenic disease\n4. Patients with hypertensive emergencies and urgency\n5. Patients with active malignancies\n6. Patients with severe hepatic dysfunction\n7. Patients with severe renal dysfunction with oliguria or anuria\n8. Pregnant, possibly pregnant, or lactating patients\n9. Patients with a history of hypersensitivity to the components of dotinurad and febuxostat\n10. Patients receiving mercaptopurine hydrate or azathioprine\n11. Other patients deemed inappropriate for this study by the investigator","ALL","20 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The effect of dotinurad on CAVI (cardio-ankle vascular index) will be compared with that of febuxostat in patients with hyperuricemia complicated by hypertension.",[27,28],"Hyperuricemia or Gout","Hypertension",[30,31,32,33],"Febuxostat","Dotinurad","CAVI","Arterial stiffness","RECRUITING","2025-12-07",{"date":37,"type":38},"2025-12-15","ACTUAL",{"date":40,"type":38},"2025-03-28",{"date":42,"type":21},"2030-03-31",{"name":44,"class":45},"Saga University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100593155","clinical-efficacy-trial-of-burdock-root-extract-in-patients-with-asymptomatic-hyperuricaemia-100593155","NCT07002762","Clinical Efficacy Trial of Burdock Root Extract in Patients With Asymptomatic Hyperuricaemia","Multicentre, Double-blind, Randomized, Placebo-controlled Trial of Clinical Efficacy of Burdock Root Extract in Patients With Asymptomatic Hyperuricaemia","Inclusion Criteria:\n\n* Hyperuricaemia confirmed by a laboratory, uric acid level from 360 to 540 μmol\u002FL in women and from 420 to 540 μmol\u002FL in men;\n\n  * Age from 35 to 65 years at the baseline;\n  * Patients examined by an experienced specialist not revealing any clinical evidences of gout or other somatic consequences of hyperuricaemia;\n  * Not taking any other nutritional additives;\n  * Women of reproductive age having negative pregnancy test at the baseline and at the end of the trial;\n  * Not taking any diuretics, or their administration based on a regimen usual for a patient, without changes;\n  * Not taking part in any other clinical trials;\n  * Consent and voluntarily signed informed consent form for participation in the clinical trial.\n\nExclusion Criteria:\n\n* Age \\\u003C35 or \\>65 years;\n* Fever (above 36.8 оС);\n* Pregnancy and lactation;\n* Patients with any somatic evidences of hyperuricaemia including gout taking antigout drugs during or within 6 months before the trial;\n* Patients with mental disorders \u002F taking antipsychotics or antidepressants;\n* Patients not giving (informed) consent to participate in the trial;\n* Patients causing doubts of the study doctor as to their motivation to comply with the trial;\n* Presence of any concomitant decompensated diseases or acute conditions able to influence results of the trial;\n* Alcohol abuse and drug addiction;\n* Changes in taking diuretics within a month before and during the trial;\n* Participation in any other clinical trial;\n* Taking any nutritional additives.","35 Years","65 Years",{"count":57,"type":21},100,[59],"NA","Multicentre, double-blind, randomized, placebo-controlled trial of the clinical efficacy of burdock root extract in patients with asymptomatic hyperuricemia, with the primary objective to assess the efficacy of the use of burdock root extract in patients with asymptomatic hyperuricaemia versus placebo",[27],"2025-07-29",{"date":64,"type":38},"2025-07-30",{"date":66,"type":38},"2025-03-12",{"date":68,"type":21},"2025-09-30",{"name":70,"class":71},"OMNIFARMA LLC","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100590378","phase-4-exploratory-study-on-the-treatment-of-gout-with-potassium-citrate-sustained-release-tablets-100590378","NCT06966635","Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets","Inclusion Criteria:\n\n* Meet the diagnostic criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) for gout in 2015\n* Age 18-70 years old, gender is not limited\n* The interval between the most recent acute onset of gout is at least \\> 2 weeks\n* Routine treatment with stable dose of uric-lowering drugs for \\> 4 weeks\n* For women who are likely to become pregnant, pregnancy tests must be negative, they must not be lactating, they must be using an investigator-approved method of contraception, and they must agree to maintain this method of contraception throughout the study\n* Study participants were informed, voluntarily signed informed consent, and agreed to participate in all visits, examinations, and treatments as required by the trial protocol\n* Informed consent to the purpose and content of the research.\n\nExclusion Criteria:\n\n* Acute gout flare\n* Secondary gout caused by kidney disease, blood disease, or taking certain drugs, tumor radiotherapy and chemotherapy\n* Severe and unstable cardiovascular and cerebrovascular diseases (such as unstable angina pectoris, coronary angiogenesis, cerebral angiogenesis, transient ischemic attack, congestive heart failure, etc.), acute and difficult to control diseases, chronic diffuse connective tissue disease, xanthine urethral deposition, Lesch-Nyhan syndrome, untreated thyroid disease or kidney stones, treatment Patients with severe hypertension (blood pressure \\> 160\u002F100mmHg) or diabetes (fasting blood glucose \\> 11.1mmol\u002FL) and organ transplantation that were not effectively controlled later\n* People who are allergic, have a history of allergy to test-related drugs (febuxosita tablets, allopurinol tablets, benzbromarone, etoracoxib, colchicine, potassium citrate, etc.) or are allergic to test-related drug components\n* Active peptic ulcer or ulcer with bleeding and perforation, severe chronic diarrhea or recurrent skin disease in the past year\n* Blood white blood cell count \\\u003C 3.0x109\u002FL, hemoglobin \\\u003C 90g\u002FL, platelet count \\\u003C 100x109\u002FL, or other blood system diseases (such as severe anemia, idiopathic thrombocytopenic purpura, spleen enlargement, coagulation dysfunction, etc.)\n* Active stage of liver disease or abnormal liver function (ALT or AST≥2 times the upper limit of normal)\n* Patients with abnormal renal function (eGFR≤60ml\u002Fmin\u002F1.73m\\^2)\n* Patients with elevated blood potassium (5.5mmol\u002FL) may have diseases or factors that may lead to hyperkalemia, such as type IV renal tubular acidosis and widespread tissue injury\n* Urine PH value \\> 6.5 during screening\n* Combined use of the following drugs: Contains salicylate drugs such as aspirin (\\> 300mg\u002Fd), thiazide diuretics, potassium diuretics such as amphenopterine, Amiloride, ACEI, azathioprine, 6-mercaptopurine, theophylline, losartan, cyclosporin A, cyclophospfamide, pyrazinamide, glucocorticoid (except in acute episodes), Niergoline tablets, long-term use of insulin, Digitalis\n* Women who are pregnant, planning to become pregnant or breastfeeding mental illness, no self-knowledge, unable to accurately express or can not take drugs on time\n* A history of alcohol abuse or dependence on known drugs within the last two years\n* Those who have participated or are participating in other clinical trials within three months\n* The study participant is a family member or relative of the staff of the research Center\n* Other lesions or conditions that, in the investigator's judgment, reduce or complicate enrollment.","18 Years","70 Years",{"count":81,"type":21},312,[24],"To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants were divided into the control group, the potassium citrate group and the sodium bicarbonate group. 2 alkalization groups took potassium citrate three times a day 2.16g each time, or sodium bicarbonate three times a day, 1.0g each time, on the basis of the standard uric acid-lowering treatment plan. The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable.",[27,85],"Nephrolithiasis","2025-05-04",{"date":88,"type":38},"2025-05-13",{"date":90,"type":38},"2024-04-10",{"date":92,"type":21},"2026-04-30",{"name":94,"class":45},"Huashan Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":124,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":46},"100569420","osaka-cardiometabolic-epidemiological-study-ohtori-study-part-2-100569420","NCT06694012","Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","OCES-2","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Women who may be pregnant",{"count":103,"type":21},2000,"OBSERVATIONAL","The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.",[107,108,109,28,110,111,112,27,113,114,115,116,117,118,119,120,121,122,123],"Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes","Diabetes Mellitus","Hyperglycemia","Hyperlipidemia","Dyslipidemia","Hyperuricemia, Gout","Obesity","Obesity\u002FEpidemiology","Obesity, Abdominal","Central Obesity","Visceral Fat","Chronic Kidney Disease(CKD)","Atherosclerosis","Metabolic Syndrome","Hepatic Steatosis","Insulin Sensitivity\u002FResistance",[125,28,111,112,126,127,128,129,130,131,132,121,133,134],"Type 2 Diabetes Mellitus","Hyperuricemia","obesity","Abdominal obesity","Visceral fat","Visceral adiposity","Chronic Kidney Disease","Japanese","Insulin Sensitivity","Insulin Resistance","2024-11-29",{"date":137,"type":38},"2024-12-04",{"date":139,"type":38},"2024-11-01",{"date":141,"type":21},"2050-03-31",{"name":143,"class":45},"Osaka Metropolitan University"]